The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 26, 2018

Filed:

Feb. 05, 2016
Applicant:

Ajou University Industry-academic Cooperation Foundation, Gyeonggi-do, KR;

Inventor:

You Sun Kim, Gyeonggi-do, KR;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/506 (2006.01); A61K 31/635 (2006.01); A61K 38/06 (2006.01); A61K 31/45 (2006.01); G01N 33/68 (2006.01); A61K 45/06 (2006.01); A61K 31/4178 (2006.01);
U.S. Cl.
CPC ...
A61K 31/506 (2013.01); A61K 31/4178 (2013.01); A61K 31/45 (2013.01); A61K 31/635 (2013.01); A61K 38/06 (2013.01); A61K 45/06 (2013.01); G01N 33/6893 (2013.01); G01N 2333/912 (2013.01); G01N 2800/20 (2013.01);
Abstract

The present invention relates to methods of preventing or treating skin necroptosis diseases, including administering to subjects receptor-interacting protein kinase-3 (RIP3)-mixed lineage kinase domain-like protein (MLKL) pathway blockers or dabrafenib, and method of diagnosing of skin necroptosis diseases, including detecting phosphorylated MLKL. The RIP3-MLKL pathway blockers according to the present invention directly suppress RIP3 overexpressing in skin necroptosis diseases, or inhibit phosphorylation and translocation to plasma membranes of MLKL, subsequently induced therefrom, thereby effectively preventing skin cell death via necroptosis. Thus, the present invention can prevent or treat a variety of skin diseases caused by necroptosis.


Find Patent Forward Citations

Loading…